
This paper reports the results of a survey of data monitoring practices of the 12 clinical zzso groups in cancer sponsored by the National Cancer Institute in the United zzso Most of these zzso groups conduct a large number of active clinical trials in a wide variety of zzso The number of active phase III trials in 1991 was zzso with nearly 24,000 patients entered on these zzso The survey instrument used in this paper was modified from one originally developed by zzso and zzso supplemented by questions on the responsibilities of data monitoring committees based on zzso Topics covered included general policies and procedures on the monitoring of clinical trials in these groups as well as specific questions on the responsibilities and operational procedures of formal data monitoring zzso Although formal statistical stopping rules are almost always employed in cancer trials in these zzso groups, use of a formal data monitoring committee is a relatively new, but increasing zzso For a variety of economic and practical reasons, the members of data monitoring committees for cancer trials are rarely independent of the study zzso 

